Search

Your search keyword '"Schmidinger, Manuela"' showing total 531 results
Start Over Author "Schmidinger, Manuela"
531 results on '"Schmidinger, Manuela"'

1. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data

Author

Yanagisawa, Takafumi, Mori, Keiichiro, Matsukawa, Akihiro, Kawada, Tatsushi, Katayama, Satoshi, Bekku, Kensuke, Laukhtina, Ekaterina, Rajwa, Pawel, Quhal, Fahad, Pradere, Benjamin, Fukuokaya, Wataru, Iwatani, Kosuke, Murakami, Masaya, Bensalah, Karim, Grünwald, Viktor, Schmidinger, Manuela, Shariat, Shahrokh F., and Kimura, Takahiro

Published
2024
Full Text
View/download PDF

2. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.

Author

Rini, Brian, Moslehi, Javid, Bonaca, Marc, Schmidinger, Manuela, Albiges, Laurence, Choueiri, Toni, Motzer, Robert, Atkins, Michael, Haanen, John, Mariani, Mariangela, Wang, Jing, Hariharan, Subramanian, and Larkin, James

Subjects
Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Cardiovascular System, Humans, Immune Checkpoint Inhibitors, Kidney Neoplasms, Prospective Studies, Randomized Controlled Trials as Topic, Sunitinib, Troponin T, Vascular Endothelial Growth Factor A, Ventricular Function, Left
Abstract

PURPOSE: Both immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, combination therapy could lead to major adverse CV events (MACE). Cardiac serum biomarker assessment and imaging, including left ventricular ejection fraction (LVEF) monitoring, can be used to evaluate MACE. METHODS: To our knowledge, the JAVELIN Renal 101 trial, assessing avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, is the first randomized study of ICI plus VEGFR inhibitor treatment to include prospective serial cardiac monitoring of LVEF and serum cardiac biomarkers. RESULTS: MACE (defined as grade ≥ 3 CV AEs) occurred in 31 patients (7.1%) in the combination arm and 17 patients (3.9%) in the sunitinib arm. Patients in the combination arm who had high baseline troponin T values were at higher risk of MACE versus patients with low values (MACE in 6/35 v 7/135, respectively; relative risk, 3.31; 95% CI, 1.19 to 9.22). This association was not observed in patients treated with sunitinib. Other CV baseline risk factors and serum cardiac biomarkers were not significantly predictive for MACE, although a trend toward an association with dyslipidemia was seen in the combination arm. No clinical value of on-treatment routine monitoring of LVEF in relation to MACE was observed. Although LVEF decline was significantly more frequent in the combination arm, most patients recovered, and decline was not associated with other significant cardiac events or symptoms. CONCLUSION: Patients with high baseline troponin T levels receiving ICI and VEGFR combinations may need to be monitored more closely for MACE. Routine monitoring of LVEF in asymptomatic patients is not recommended.

Published
2022

5. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Author

Barone, Carlo, Castellano, Daniel, Chevreau, Christine, Gajate Borau, Pablo, Gopalakrishnan, Srinavasan, Grande, Enrique, Hamid, Abdel, Heinzelbecker, Julia, Janssen, Martin, Kopecký, Jindřich, Kubala, Eugen, Loidl, Wolfgang, Lorch, Anja, Melichar, Bohuslav, Lainez Milagro, Nuria, Niegisch, Günter, Ohlmann, Carsten, Sacré, Anne, Sarwar, Naveed, Schinzari, Giovanni, Schrijvers, Dirk, Tartas, Sophie, Wirth, Manfred, Wolter, Pascal, Zemanova, Milanda, Grimm, Marc-Oliver, Esteban, Emilio, Barthélémy, Philippe, Schmidinger, Manuela, Busch, Jonas, Valderrama, Begoña P, Charnley, Natalie, Schmitz, Marc, Schumacher, Ulrike, Leucht, Katharina, Foller, Susan, Baretton, Gustavo, Duran, Ignacio, de Velasco, Guillermo, Priou, Frank, Maroto, Pablo, and Albiges, Laurence

Published
2023
Full Text
View/download PDF

7. Contributors

Author

Aiken, Catherine E.M., primary, Amiri, Azita, additional, Anderson, Faith L., additional, Argenson, Arthur, additional, Arita, Anna, additional, Attarian, Hrayr, additional, Berner, Alison, additional, Bhandari, Vineet, additional, Bhat, Vishwanath, additional, Bos, Angelo Jose Goncalves, additional, Bradbury, Neil A., additional, Bucher, Meghan L., additional, Burns, Jan, additional, Campesi, Ilaria, additional, Casadevall, Arturo, additional, Chiti, Hossein, additional, Christiansen, Dorte M., additional, Coad, Beth, additional, Corella, Dolores, additional, Coromilas, Ellie J., additional, de leon, Romina Garcia, additional, Devi-Chou, Virginia, additional, Dicent, Jocelyn, additional, Dorak, Mehmet Tevfik, additional, Einstein, Gillian, additional, Fajkovic, Harun, additional, Fang, Ferric C., additional, Fattore, Liana, additional, Fausto-Sterling, Anne, additional, Fazeli, Alireza, additional, Feldberg, Dov, additional, Fillingim, Roger B., additional, Franconi, Flavia, additional, Frith, Karen H., additional, Fritzen, Andreas M., additional, Fukui, Michika, additional, Galea, Liisa A.M., additional, Gazit, Dan, additional, Gazit, Zulma, additional, Gemmati, Donato, additional, Giblin, Josephine, additional, Glezerman, Marek, additional, Godakumara, Kasun, additional, Gram, Sydney, additional, Guillamon, Antonio, additional, Haga, Susanne B., additional, Hennessey, Jessica A., additional, Hihara, Masakatsu, additional, Holt, William V., additional, Hufnagel, Antonia, additional, Iwaguro, Hideki, additional, Jamialahmadi, Tannaz, additional, Joel, Daphna, additional, Jovanov, Emil, additional, Kakudo, Natsuko, additional, Kiens, Bente, additional, Kim, Jin Kyung, additional, Kirchengast, Sylvia, additional, Kochav, Stephanie M., additional, Kodithuwakku, Suranga P., additional, Kok, L.M., additional, Koopman, Peter, additional, Krut, Zoe, additional, Kuro, Atsuyuki, additional, Kuroda, Ryosuke, additional, Kushida, Satoshi, additional, Lai, Yunjia, additional, Lee, Bonnie H., additional, Lleo, Ana, additional, Lundsgaard, Anne-Marie, additional, Maggi, Adriana C., additional, Matsushita, Satoshi, additional, McCarthy, Margaret M., additional, Melloni, Alice, additional, Meloni, Maurizio, additional, Miller, Gary W., additional, Mishra, Suresh, additional, Mitsui, Toshihito, additional, Mizuno, Hiroshi, additional, Nelissen, R.G.H.H., additional, Nickl, Petr, additional, Nomura, Tatsuya, additional, Oertelt-Prigione, Sabine, additional, Oliveira-Zumda, Gabriela Guimaraes, additional, Ordovas, Jose M., additional, Parsamanesh, Negin, additional, Pelled, Gadi, additional, Puiu, Andrei A., additional, Rajah, M. Natasha, additional, Reddy, Doodipala Samba, additional, Reiner, Željko, additional, Sahebkar, Amirhossein, additional, Saita, Yoshitomo, additional, Sánchez-Serrano, Ibis, additional, Sari Motlagh, Reza, additional, Savic, Ivanka, additional, Schmidinger, Manuela, additional, Schmidt, Caleb M., additional, Schmidt, Michael A., additional, Sedlacek, Radislav, additional, Serani, Angelo, additional, Shaib, Fidaa, additional, Shariat, Shahrokh F., additional, Singh, Keshav K., additional, Sobajima, Satoshi, additional, Sokolowski, Dustin J., additional, Sokolowski, Marla B., additional, Sun, Simón(e) D., additional, Sun, Zhongxin, additional, Sung, Jihyun, additional, Syding, Linn Amanda, additional, Taneja, Veena, additional, Tautz, Diethard, additional, Thurston, Lisa M., additional, Tierney, Siobhan, additional, Tisato, Veronica, additional, Tobita, Morikuni, additional, Tollkuhn, Jessica, additional, Tsubosaka, Masanori, additional, Tucci, Valter, additional, Uribe, Carme, additional, Van Noort, A., additional, Votinov, Mikhail, additional, Walsh, Reubs J., additional, Wan, Elaine Y., additional, and Zubiaurre-Elorza, Leire, additional

Published
2023
Full Text
View/download PDF

9. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

Author

Schmidinger, Manuela, Bamias, Aristotelis, Procopio, Giuseppe, Hawkins, Robert, Sanchez, Angel Rodriguez, Vázquez, Sergio, Srihari, Narayanan, Kalofonos, Haralabos, Bono, Petri, Pisal, Chaitali Babanrao, Hirschberg, Yulia, Dezzani, Luca, Ahmad, Qasim, Jonasch, Eric, and Group, on behalf of the PRINCIPAL Study

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Kidney Disease, Cancer, Patient Safety, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Indazoles, Kidney Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Pyrimidines, Quality of Life, Sulfonamides, Survival Rate, Treatment Outcome, Young Adult, PRINCIPAL Study Group, Observational, Pazopanib, Real‐world, Renal cell carcinoma, Tyrosine kinase inhibitor, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundReal-world data are essential to accurately assessing efficacy and toxicity of approved agents in everyday practice. PRINCIPAL, a prospective, observational study, was designed to confirm the real-world safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC).Subjects, materials, and methodsPatients with clear cell advanced/metastatic RCC and a clinical decision to initiate pazopanib treatment within 30 days of enrollment were eligible. Primary objectives included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), relative dose intensity (RDI) and its effect on treatment outcomes, change in health-related quality of life (HRQoL), and safety. We also compared characteristics and outcomes of clinical-trial-eligible (CTE) patients, defined using COMPARZ trial eligibility criteria, with those of non-clinical-trial-eligible (NCTE) patients. Secondary study objectives were to evaluate clinical efficacy, safety, and RDI in patient subgroups.ResultsSix hundred fifty-seven patients were enrolled and received ≥1 dose of pazopanib. Median PFS and OS were 10.3 months (95% confidence interval [CI], 9.2-12.0) and 29.9 months (95% CI, 24.7 to not reached), respectively, and the ORR was 30.3%. HRQoL showed no or little deterioration over time. Treatment-related serious adverse events (AEs) and AEs of special interest occurred in 64 (9.7%), and 399 (60.7%) patients, respectively. More patients were classified NCTE than CTE (85.2% vs. 14.8%). Efficacy of pazopanib was similar between the two groups.ConclusionPRINCIPAL confirms the efficacy and safety of pazopanib in patients with advanced/metastatic RCC in a real-world clinical setting.Implications for practicePRINCIPAL is the largest (n = 657) prospective, observational study of pazopanib in patients with advanced/metastatic renal cell carcinoma, to the authors' knowledge. Consistent with clinical trial results that often contain specific patient types, the PRINCIPAL study demonstrated that the effectiveness and safety of pazopanib is similarly safe and effective in patients with advanced kidney cancer in a real-world clinical setting. The PRINCIPAL study showed that patients with advanced kidney cancer who are treated with first-line pazopanib generally do not show disease progression for approximately 10 months and generally survive for nearly 30 months.

Published
2019

10. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis

Author

Mori, Keiichiro, Quhal, Fahad, Yanagisawa, Takafumi, Katayama, Satoshi, Pradere, Benjamin, Laukhtina, Ekaterina, Rajwa, Pawel, Mostafaei, Hadi, Sari Motlagh, Reza, Kimura, Takahiro, Egawa, Shin, Bensalah, Karim, Karakiewicz, Pierre I., Schmidinger, Manuela, and Shariat, Shahrokh F.

Published
2022
Full Text
View/download PDF

13. Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach

Author

Laukhtina, Ekaterina, Schuettfort, Victor M., D’Andrea, David, Pradere, Benjamin, Quhal, Fahad, Mori, Keiichiro, Sari Motlagh, Reza, Mostafaei, Hadi, Katayama, Satoshi, Grossmann, Nico C., Rajwa, Pawel, Karakiewicz, Pierre I., Schmidinger, Manuela, Fajkovic, Harun, Enikeev, Dmitry, and Shariat, Shahrokh F.

Published
2022
Full Text
View/download PDF

14. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.

Author

Motzer, Robert J., primary, Penkov, Konstantin, additional, Uemura, Hirotsugu, additional, Campbell, Matthew T, additional, Kollmannsberger, Christian K., additional, Lee, Jae-Lyun, additional, Venugopal, Balaji, additional, Van Den Eertwegh, Alfonsus, additional, Negrier, Sylvie, additional, Gurney, Howard, additional, Albiges, Laurence, additional, Berger, Raanan, additional, Haanen, John, additional, Rini, Brian I., additional, Larkin, James, additional, Schmidinger, Manuela, additional, Sandner, Robin, additional, Wang, Jing, additional, Di Pietro, Alessandra, additional, and CHOUEIRI, Toni K., additional

Published
2024
Full Text
View/download PDF

19. First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy.

Author

Yanagisawa, Takafumi, Kawada, Tatsushi, Bekku, Kensuke, Laukhtina, Ekaterina, Rajwa, Pawel, von Deimling, Markus, Chlosta, Marcin, Quhal, Fahad, Pradere, Benjamin, Karakiewicz, Pierre I., Mori, Keiichiro, Kimura, Takahiro, Shariat, Shahrokh F., and Schmidinger, Manuela

Subjects
IMMUNE checkpoint inhibitors, RENAL cell carcinoma, CANCER patients, RANDOMIZED controlled trials, NIVOLUMAB
Abstract

Objective: To compare the differential efficacy of first‐line immune checkpoint inhibitor (ICI)‐based combined therapies among patients with intermediate‐ and poor‐risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. Patients and Methods: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first‐line ICI‐based combined therapies. We performed network meta‐analysis (NMA) to compare the outcomes, including progression‐free survival (PFS) and objective response rates (ORRs), in patients with intermediate‐ and poor‐risk mRCC; we also assessed treatment‐related adverse events. Results: Overall, seven RCTs were included in the meta‐analyses and NMAs. Treatment ranking analysis revealed that pembrolizumab + lenvatinib (99%) had the highest likelihood of improved PFS, followed by nivolumab + cabozantinib (79%), and nivolumab + ipilimumab + cabozantinib (77%). Notably, compared to nivolumab + cabozantinib, adding ipilimumab to nivolumab + cabozantinib did not improve PFS (hazard ratio 1.02, 95% confidence interval 0.72–1.43). Regarding ORRs, treatment ranking analysis also revealed that pembrolizumab + lenvatinib had the highest likelihood of providing better ORRs (99.7%). The likelihoods of improved PFS and ORRs of pembrolizumab + lenvatinib were true in both International Metastatic RCC Database Consortium (IMDC) risk groups. Conclusions: Our analyses confirmed the robust efficacy of pembrolizumab + lenvatinib as first‐line treatment for patients with intermediate or poor IMDC risk mRCC. Triplet therapy did not result in superior efficacy. Considering both toxicity and the lack of mature overall survival data, triplet therapy should only be considered in selected patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field

Author

Marhold, Maximilian, Topakian, Thais, Agis, Hermine, Bartsch, Rupert, Berghoff, Anna S., Brodowicz, Thomas, Fuereder, Thorsten, Ilhan-Mutlu, Aysegül, Kiesewetter, Barbara, Krainer, Michael, Locker, Gottfried J., Marosi, Christine, Prager, Gerald, Schmidinger, Manuela, Thallinger, Christiane, Zöchbauer-Müller, Sabine, Raderer, Markus, Preusser, Matthias, and Lamm, Wolfgang

Published
2020
Full Text
View/download PDF

31. Metastatic Translocated Renal Cell Carcinoma in a Kidney Transplant Patient - a Case Report and Review of the Literature.

Author

Kläger, Johannes, Schmidinger, Manuela, Oszwald, André, Wasinger, Gabriel, Fajkovic, Harun, and Compérat, Eva

Subjects
*RENAL cell carcinoma, *KIDNEY transplantation, *LITERATURE reviews, *DEAD, *BREAST, *IMMUNE checkpoint inhibitors, *TRANSPLANTATION of organs, tissues, etc.
Abstract

TFEB -altered renal cell carcinomas are rare tumours. Here, we report the exceptional case of such a tumour in the setting of solid organ transplantation and with already metastatic disease at the time of diagnosis. The primary tumour occurred in the native kidney and only focally showed biphasic morphology whereas the metastasis, among others to the transplant kidney, showed nonspecific, albeit different morphology, but both had consistent TFEB translocation. Treatment with the immune checkpoint inhibitor pembrolizumab together with the multi-kinase inhibitor lenvatinib achieved partial response 14 months after diagnosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non‐metastatic renal cell carcinoma: Systematic review and meta‐analysis

Author

Majdoub, Muhammad, primary, Yanagisawa, Takafumi, additional, Quhal, Fahad, additional, Laukhtina, Ekaterina, additional, von Deimling, Markus, additional, Kawada, Tatsushi, additional, Rajwa, Pawel, additional, Bianchi, Alberto, additional, Pallauf, Maximilian, additional, Mostafaei, Hadi, additional, Chlosta, Marcin, additional, Pradere, Benjamin, additional, Karakiewicz, Pierre I., additional, Schmidinger, Manuela, additional, Rub, Ronen, additional, and Shariat, Shahrokh F., additional

Published
2023
Full Text
View/download PDF

35. Association between age and efficacy of first-line immunotherapy-based combination therapies for mRCC: a meta-analysis

Author

Yanagisawa, Takafumi, primary, Quhal, Fahad, additional, Kawada, Tatsushi, additional, Bekku, Kensuke, additional, Laukhtina, Ekaterina, additional, Rajwa, Pawel, additional, Deimling, Markus von, additional, Chlosta, Marcin, additional, Pradere, Benjamin, additional, Karakiewicz, Pierre I, additional, Mori, Keiichiro, additional, Kimura, Takahiro, additional, Schmidinger, Manuela, additional, and Shariat, Shahrokh F, additional

Published
2023
Full Text
View/download PDF

36. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

Author

Grimm, Marc-Oliver, primary, Esteban, Emilio, additional, Barthélémy, Philippe, additional, Schmidinger, Manuela, additional, Busch, Jonas, additional, Valderrama, Begoña P, additional, Charnley, Natalie, additional, Schmitz, Marc, additional, Schumacher, Ulrike, additional, Leucht, Katharina, additional, Foller, Susan, additional, Baretton, Gustavo, additional, Duran, Ignacio, additional, de Velasco, Guillermo, additional, Priou, Frank, additional, Maroto, Pablo, additional, Albiges, Laurence, additional, Barone, Carlo, additional, Castellano, Daniel, additional, Chevreau, Christine, additional, Gajate Borau, Pablo, additional, Gopalakrishnan, Srinavasan, additional, Grande, Enrique, additional, Hamid, Abdel, additional, Heinzelbecker, Julia, additional, Janssen, Martin, additional, Kopecký, Jindřich, additional, Kubala, Eugen, additional, Loidl, Wolfgang, additional, Lorch, Anja, additional, Melichar, Bohuslav, additional, Lainez Milagro, Nuria, additional, Niegisch, Günter, additional, Ohlmann, Carsten, additional, Sacré, Anne, additional, Sarwar, Naveed, additional, Schinzari, Giovanni, additional, Schrijvers, Dirk, additional, Tartas, Sophie, additional, Wirth, Manfred, additional, Wolter, Pascal, additional, and Zemanova, Milanda, additional

Published
2023
Full Text
View/download PDF

37. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial

Author

Grimm, Marc-Oliver, primary, Oya, Mototsugu, additional, Choueiri, Toni K., additional, Motzer, Robert M., additional, Schmidinger, Manuela, additional, Quinn, David I., additional, Gravis-Mescam, Gwenaelle, additional, Verzoni, Elena, additional, Van den Eertwegh, Alfonsus J.M., additional, di Pietro, Alessandra, additional, Mariani, Mariangela, additional, Wang, Jing, additional, Thomaidou, Despina, additional, and Albiges, Laurence, additional

Published
2023
Full Text
View/download PDF

39. Role of clinicopathological variables in predicting recurrence and survival outcomes after surgery for non‐metastatic renal cell carcinoma: Systematic review and meta‐analysis.

Author

Majdoub, Muhammad, Yanagisawa, Takafumi, Quhal, Fahad, Laukhtina, Ekaterina, von Deimling, Markus, Kawada, Tatsushi, Rajwa, Pawel, Bianchi, Alberto, Pallauf, Maximilian, Mostafaei, Hadi, Chlosta, Marcin, Pradere, Benjamin, Karakiewicz, Pierre I., Schmidinger, Manuela, Rub, Ronen, and Shariat, Shahrokh F.

Subjects
RENAL cell carcinoma, SURVIVAL rate, NEPHRECTOMY, SURGICAL margin, CLINICAL pathology, RENAL veins
Abstract

Renal cell carcinoma (RCC) represents 2% of all diagnosed malignancies worldwide, with disease recurrence affecting 20% to 40% of patients. Existing prognostic recurrence models based on clinicopathological features continue to be a subject of controversy. In this meta‐analysis, we summarized research findings that explored the correlation between clinicopathological characteristics and post‐surgery survival outcomes in non‐metastatic RCC patients. Our analysis incorporates 99 publications spanning 140 568 patients. The study's main findings indicate that the following clinicopathological characteristics were associated with unfavorable survival outcomes: T stage, tumor grade, tumor size, lymph node involvement, tumor necrosis, sarcomatoid features, positive surgical margins (PSM), lymphovascular invasion (LVI), early recurrence, constitutional symptoms, poor performance status (PS), low hemoglobin level, high body‐mass index (BMI), diabetes mellitus (DM) and hypertension. All of which emerged as predictors for poor recurrence‐free survival (RFS) and cancer‐specific survival. Clear cell (CC) subtype, urinary collecting system invasion (UCSI), capsular penetration, perinephric fat invasion, renal vein invasion (RVI) and increased C‐reactive protein (CRP) were all associated with poor RFS. In contrast, age, sex, tumor laterality, nephrectomy type and approach had no impact on survival outcomes. As part of an additional analysis, we attempted to assess the association between these characteristics and late recurrences (relapses occurring more than 5 years after surgery). Nevertheless, we did not find any prediction capabilities for late disease recurrences among any of the features examined. Our findings highlight the prognostic significance of various clinicopathological characteristics potentially aiding in the identification of high‐risk RCC patients and enhancing the development of more precise prediction models. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).

Author

Grünwald, Viktor, Winquist, Eric, Peer, Avivit, Schmidinger, Manuela, Procopio, Giuseppe, Barthelemy, Philippe, Lee, Jae-Lyun, Rudman, Sarah, Kadambi, Ananth, Pandey, Anuja, Neupane, Binod, Fahrbach, Kyle, Purushotham, Sneha, Jones, Michael, Egodage, Sonya, Kashyap, Ananth, Hauck, Wendy, and Pan, Janice

Published
2024
Full Text
View/download PDF

47. Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types

Author

Robinson, Irina, primary, Hochmair, Maximilian Johannes, additional, Schmidinger, Manuela, additional, Absenger, Gudrun, additional, Pichler, Martin, additional, Nguyen, Van Anh, additional, Richtig, Erika, additional, Rainer, Barbara Margaretha, additional, Ay, Leyla, additional, Jansen, Christian, additional, Pacífico, Cátia, additional, Knabl, Alexander, additional, Sladek, Barbara, additional, Gasche, Nikolaus, additional, and Valipour, Arschang, additional

Published
2023
Full Text
View/download PDF

48. Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial

Author

Grimm, Marc-Oliver, Oya, Mototsugu, Choueiri, Toni K., Motzer, Robert J., Schmidinger, Manuela, Quinn, David I., Gravis-Mescam, Gwenaelle, Verzoni, Elena, Van den Eertwegh, Alfonsus J.M., di Pietro, Alessandra, Mariani, Mariangela, Wang, Jing, Thomaidou, Despina, and Albiges, Laurence

Published
2024
Full Text
View/download PDF

50. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Author

Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Tannir, Nizar M, Mainwaring, Paul N, Rini, Brian I, Hammers, Hans J, Donskov, Frede, Roth, Bruce J, Peltola, Katriina, Lee, Jae Lyun, Heng, Daniel Y C, Schmidinger, Manuela, Agarwal, Neeraj, Sternberg, Cora N, McDermott, David F, Aftab, Dana T, Hessel, Colin, Scheffold, Christian, Schwab, Gisela, Hutson, Thomas E, Pal, Sumanta, and Motzer, Robert J

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results